Roxadustat

Roxadustat
Clinical data
Trade names	Evrenzo
Other names	FG-4592, ASP1517, AZD9941
License data	EU EMA: by INN;
Routes of; administration	By mouth
ATC code	B03XA05 (WHO) ;
Legal status
Legal status	EU: Rx-only; In general: ℞ (Prescription only);
Identifiers
	IUPAC name 2-[(4-Hydroxy-1-methyl-7-phenoxyisoquinoline-3-carbonyl)amino]acetic acid;
CAS Number	808118-40-3;
PubChem CID	11256664;
DrugBank	DB04847;
ChemSpider	9431690;
UNII	X3O30D9YMX;
KEGG	D10593;
CompTox Dashboard (EPA)	DTXSID60230644 ;
ECHA InfoCard	100.245.356
Chemical and physical data
Formula	C19H16N2O5
Molar mass	352.346 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CC1=NC(=C(C2=C1C=C(C=C2)OC3=CC=CC=C3)O)C(=O)NCC(=O)O;
	InChI InChI=1S/C19H16N2O5/c1-11-15-9-13(26-12-5-3-2-4-6-12)7-8-14(15)18(24)17(21-11)19(25)20-10-16(22)23/h2-9,24H,10H2,1H3,(H,20,25)(H,22,23); Key:YOZBGTLTNGAVFU-UHFFFAOYSA-N;

Roxadustat, sold under the brand name Evrenzo, is an anti-anemia medication. Roxadustat is a HIF prolyl-hydroxylase inhibitor that increases endogenous production of erythropoietin and stimulates production of hemoglobin and red blood cells. It was investigated in clinical trials for the treatment of anemia caused by chronic kidney disease (CKD). It is taken by mouth. The drug was developed by FibroGen, in partnership with AstraZeneca.

The most common side effects include hypertension (high blood pressure), vascular access thrombosis (formation of blood clots in the blood vessels associated with dialysis), diarrhea, peripheral edema (swelling especially of the ankles and feet), hyperkalemia (high blood potassium levels) and nausea (feeling sick).

Roxadustat received its first global approval in China on 17 December 2018, for the treatment of anemia caused by CKD in patients who are dialysis-dependent. It was approved in Japan in 2019, for the treatment of anemia caused by CKD in patients on dialysis, and in 2020 for patients not on dialysis. Roxadustat was approved for medical use in the European Union in August 2021.

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.